The role of immunotherapy in HER2 altered NSCLC remains unclear and while there is unlikely to be a clinical trial of immunotherapy specifically in this patient population, a better understanding of the tumor immune microenvironment in HER2 altered NSCLC could allow for more rational use of these agents in this patient population. This evidence concerns the gene ERBB2 and neoplasm.